Novel aspects of mevalonate pathway inhibitors as antitumor agents.
about
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugsA novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosisBeyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescenceChemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasisAnti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells.Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growthSimvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma.Chemically induced mouse liver tumors are resistant to treatment with atorvastatin.Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Statin Use and Its Impact on Survival in Pancreatic Cancer PatientsEffect of Lipophilic and Hydrophilic Statins on Breast Cancer Risk in Thai Women: A Cross-sectional StudyBisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism.Statins and Breast Cancer: Future Directions in Chemoprevention.Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathwayDual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal CancerDownregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine OsteosarcomaThe Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics.γδ T cell therapy for the treatment of non-small cell lung cancer.T lymphocyte regulation by mevalonate metabolism.The Gut-Liver-Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease.Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.Inhibition of autophagy augments apoptosis in human oral squamous cell carcinoma under nutrient depletion.In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.Regulation of Metabolic Activity by p53.Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
P2860
Q21245491-0DE84BB2-4F8B-435C-8151-B7918A5F64BDQ26774351-CCEE78BF-A382-421D-B900-785BF35C6109Q27011650-B611A2F5-BB65-4390-908F-2ED70C675872Q28539314-51DD76E9-019E-46DD-B3D9-63C8B47C45ADQ33638286-E74555B4-66F2-4996-BB6D-685B61C1A972Q33716678-DE3D51D5-C207-480E-8BDB-C0A0F52975AAQ34507114-B3D48360-AE8A-45FB-8941-7E4F6908A47FQ34574121-77A0FC55-BD50-41A2-9E5A-5D9E3EA72A9AQ34729901-BF84B0D6-26AF-4762-81AB-8DD2E4E49B4BQ34757109-BEA11171-E94A-4824-8EC8-19E9F1D48D9EQ35335391-D281C48A-B518-4BD9-9BAB-7B68049330E2Q35915762-18BD34AC-28FF-468B-914B-D7D9125BCF6BQ36021018-DABCED5F-89E8-440F-A767-54681D49DE16Q36544608-40C09394-B63F-4C75-AB6A-C182430CEC36Q36557448-7457B8B7-54AC-486C-B51B-924071D139F7Q36907149-6E47D641-C245-4C7C-93C1-7290DDDD44B8Q36993452-FAD9CA15-BF81-4D98-8609-FD3146CFC30BQ37015751-2C9427DE-A824-431C-B7F4-D8CC89E749E6Q37087037-0ED67734-D41C-4E8D-BB66-24E6A79835ADQ37119810-ACDDEF23-13F2-4785-9E33-B176CD693D0EQ37189557-1EC9A277-968B-4966-BC3D-44F0AE051CE8Q37221691-E65AC855-DBF2-4A9B-BBC6-F477ED856A47Q37384979-7F64D804-7535-4260-A356-34C366965DBBQ37396993-5E8BF653-E2AF-49BF-9BAE-B196A5F969ECQ37734257-CA8F7BF6-D058-4142-8E70-EE1257CA6489Q38149124-B12EE5B9-57E8-4486-9F12-D7FBF7A7A9F8Q38390100-A895C652-8EE9-42AE-8A41-1FD5E5465986Q38398684-C81CF209-7555-44E1-9F77-72B74807B15DQ38608866-14971FA7-95E9-41EC-90CF-25747F88C363Q38624909-C29A14D0-84DF-43F2-891E-D4189D287CA0Q38758048-944E72BE-4FF0-4815-8D29-090909E718C6Q38823772-0C6E741F-DF19-4375-8859-B92962C707D3Q38832228-48CE3E94-8621-4860-ABA3-09AC5A16B8D0Q38957404-2725020D-C259-43A9-9395-AA6A45E2A1BDQ38968601-880C76E7-62AF-4F8E-8B07-AE9F1B3EE745Q39201898-2B7E5754-8BCA-4147-84E6-28A1B101EAD7Q39317705-9D0BED08-C579-457C-B01E-2595EAAC72D8Q39322285-87803470-A5B3-451E-8FCA-34BFC6F2FD7FQ39455228-13600230-673E-4D9E-B6F2-1092209D3C1BQ40207403-8DA3D5A4-9D84-4BCF-BE67-A410805513B5
P2860
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@ast
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@en
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@nl
type
label
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@ast
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@en
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@nl
prefLabel
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@ast
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@en
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@nl
P1476
Novel aspects of mevalonate pathway inhibitors as antitumor agents.
@en
P2093
Martin Thurnher
Oliver Nussbaumer
P304
P356
10.1158/1078-0432.CCR-12-0489
P407
P577
2012-04-23T00:00:00Z